ResMed Inc. (RMD) Aandelenanalyse

Bedrijfsoverzicht

ResMed Inc. is a leading developer, manufacturer, and distributor of medical devices and cloud-based software applications designed to diagnose, treat, and manage respiratory disorders across the United States and international markets. The company operates within the Healthcare sector, specifically specializing in the Medical Instruments & Supplies industry, which implies a focus on high-quality, regulated products essential for patient care. This entity employs a workforce of 10,600 individuals to support its extensive product portfolio and global distribution network. With a market capitalization of $33.41 billion and annual revenue reaching $5.40 billion, the company demonstrates significant scale and market penetration. These valuation and revenue figures indicate that ResMed holds a substantial position in the respiratory care market, reflecting strong investor confidence in its long-term business model and its ability to generate consistent cash flows from a diversified range of sleep and breathing health solutions.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $5.40 billion, with net income of $1.49 billion and EBITDA standing at $2.02 billion. The substantial gap between revenue and net income reveals a robust cost structure where operating expenses, such as cost of goods sold and administrative costs, consume approximately 37.5% of total revenue, yet the business retains significant profitability. ResMed generated $1.42 billion in free cash flow, a figure that aligns with its cash balance and indicates strong financial flexibility for capital allocation, debt repayment, or strategic acquisitions. The company's gross margin of 61.5% highlights the high value and pricing power of its proprietary medical devices, while the operating margin of 35.2% and profit margin of 27.5% further demonstrate efficient management of overhead and exceptional overall profitability. On the balance sheet, ResMed holds $1.42 billion in cash against $847.72 million in debt, resulting in a debt-to-equity ratio of 13.41, which suggests a net cash position that is highly conservative and low-risk for creditors. Additionally, the current ratio of 3.06 indicates that the company possesses more than three times the current assets necessary to cover its short-term liabilities, confirming excellent short-term liquidity and the ability to meet obligations without distress. Management effectiveness is underscored by a return on equity of 25.7% and a return on assets of 14.7%, metrics that reveal the company's ability to generate substantial returns relative to the shareholders' equity and the total asset base employed.

Waarderingsbeoordeling

ResMed trades with a trailing twelve-month P/E ratio of 22.62 and a forward P/E of 18.80, implying that the market expects earnings growth to accelerate in the future, as the forward multiple is significantly lower than the trailing multiple. The price-to-book ratio stands at 5.27, indicating that the market values the company at more than five times its book value, which reflects a premium assigned to its intangible assets, brand strength, and recurring revenue model rather than just its tangible net worth. Alternative valuation metrics provide further context, with a price-to-sales ratio of 6.19 and an EV/EBITDA of 16.18, suggesting that investors are willing to pay a premium for each dollar of sales and earnings due to the stability of the healthcare sector. Regarding price action, the stock has traded between a 52-week low of $202.00 and a 52-week high of $293.81, meaning the current share price sits somewhere within this established range relative to its volatility history. The beta of 0.93 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it behaves somewhat as a defensive stock that moves in tandem with the overall market but with less sensitivity to broad economic fluctuations.

Growth & Income

ResMed is currently experiencing revenue growth of 11.0% year-over-year and earnings growth of 14.5% year-over-year, which demonstrates that earnings are expanding at a faster rate than revenue. This divergence implies that the company is benefiting from operating leverage, where fixed costs are spread over a growing revenue base, thereby increasing profit margins as sales volume increases. As a consistent dividend payer, the company offers a dividend yield of 1.1% with a payout ratio of 22.4%, a level that is highly sustainable given the company's strong cash generation and conservative leverage. The low payout ratio combined with robust free cash flow suggests that ResMed retains the majority of its earnings to reinvest in research and development, expand its product lines, or acquire complementary technologies, thereby fueling future growth rather than distributing all profits to shareholders. Overall, the company presents a profile that balances steady income generation through dividends with significant growth potential driven by double-digit earnings expansion and operational efficiency in the competitive medical device landscape.